Published on FierceBiotech (http://www.fiercebiotech.com)

Motavizumab - Next gen biotech blockbusters

By maureen
Created Jul 8 2008 - 2:54pm

Drug: Motavizumab
Company: MedImmune/AstraZeneca

Scoop: When AstraZeneca spent $15.6 billion to acquire MedImmune, it picked up motavizumab in the process. Motavizumab, to be sold as Numax, is a fully humanized monoclonal antibody to prevent respiratory syncytial virus infection in infants--a condition which sends about 125,000 infants to the hospital each year. A BLA was submitted back in February and an FDAdecision is expected sometime this year.

Related Articles:
AstraZeneca merges MedImmune, CAT [1]
Numax data gives boost to MedImmune [2]

Previous: The next generation of biotech blockbusters [3]Index [3]Next: Denosumab [4]
Source URL: http://www.fiercebiotech.com/special-reports/motavizumab-next-gen-biotech-blockbusters

Links:
[1] http://www.fiercebiotech.com/story/astrazeneca-merges-medimmune-cat/2007-10-22
[2] http://www.fiercebiotech.com/story/numax-data-gives-boost-to-medimmune/2006-11-08
[3] http://www.fiercebiotech.com/special-reports/next-generation-biotech-blockbusters
[4] http://www.fiercebiotech.com/special-reports/denosumab-next-gen-biotech-blockbusters